Wed, July 20, 2011
[ Wed, Jul 20th 2011 ] - Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ] - Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ] - Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011
Tue, July 12, 2011
Mon, July 11, 2011
Sun, July 10, 2011
Sat, July 9, 2011
Fri, July 8, 2011
Thu, July 7, 2011
Wed, July 6, 2011
[ Wed, Jul 06th 2011 ] - Market Wire
Larry Renfro Named CEO of Optum
Tue, July 5, 2011
Mon, July 4, 2011
Sat, July 2, 2011
Fri, July 1, 2011
Thu, June 30, 2011
[ Thu, Jun 30th 2011 ] - Market Wire
KCI???NPWT????????????
Wed, June 29, 2011
Tue, June 28, 2011
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011

The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Poniard Pharmaceuticals, Inc.


//health-fitness.news-articles.net/content/2011/ .. nvestigation-of-poniard-pharmaceuticals-inc.html
Published in Health and Fitness on Friday, July 8th 2011 at 14:40 GMT by Market Wire   Print publication without navigation


NEW YORK--([ BUSINESS WIRE ])--Levi & Korsinsky is investigating the Board of Directors of Poniard Pharmaceuticals, Inc. (aPoniarda or the aCompanya) (NASDAQ: PARD) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to ALLOZYNE, Inc. Under the terms of the transaction, Poniard will issue shares of its common stock to ALLOZYNE stockholders based on an exchange ratio to be determined prior to the transactiona™s closing. The exchange ratio has been calculated using the 5-day average closing sales price of Poniard common stock prior to the merger announcement, or $0.2270 per share. Former Poniard shareholders are expected to own approximately 35% of the combined company on a fully diluted basis.

Click here to learn how to join the action: [ http://www.zlk.com/poniard-pharmaceuticals-pard ], or call: 877-363-5972.

The investigation concerns whether the Poniard Board of Directors breached their fiduciary duties to Poniard stockholders by failing to adequately shop the Company before entering into this transaction which is dilutive to Poniard shareholders. In particular, at least one analyst set a target price for Poniard stock at $1 per share.

If you own common stock in Poniard and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit [ http://www.zlk.com/poniard-pharmaceuticals-pard.html ].

Levi & Korsinsky is a national firm with offices in New York, California and Washington D.C. The firm has extensive expertise in prosecuting investor securities litigation involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.


Publication Contributing Sources